Russia has one of the highest prevalences of paediatric chronic hepatitis C infection (CHC). Our aim was to provide a detailed characterization of children and adolescents with CHC including treatment outcomes. Thus, an observational study of children with CHC aged <18 years was conducted in three hepatology centres from This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
| INTRODUC TI ON
Russia has one of the highest burdens of HCV infection globally with an estimated seroprevalence of 4.3% and the highest absolute number of chronic infections of 3.2 million. 5 In 2013, a CHC prevalence of 336 per 100 000 population was reported in the HCV national surveillance system, reaching 670 per 100 000 in some regions; overall CHC incidence was 40 per 100 000 per year but varied widely across regions, from 13 to 68. 6 Over the last few years, the reported CHC incidence has gradually decreased to 35-36 per 100 000 in 2016-2017. 7 Genotype (GT) 1b is the most prevalent genotype accounting for 55% of all cases, followed by GT3 (35%).
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In 2013, the reported CHC prevalence was 14 per 100 000 children aged 1-14, 6 with the corresponding incidence of 1.75 per 100 000 children. 9 Similar to adults, there is a downward trend observed over the last years with the reported incidence of 1.33-1.44
per 100 000 children in 2016-2017. 7 Vertical transmission was the most common mode of acquisition accounting for two-thirds of new infections, with anti-HCV prevalence among pregnant women reported as 1.3% in 2011-2012. 6 Route of transmission was not determined for 21% of all infected children aged ≤14 years.
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Our aim was to provide a detailed characterization of children and adolescents with chronic HCV with regard to mode of acquisition, HCV genotype, clinical status, type of treatment and treatment outcomes in three paediatric hepatology centres in Russia in the pre direct-acting antivirals (DAA) era.
| MATERIAL S AND ME THODS
An observational study of children and adolescents with chronic A total of 100 children seen consecutively in each centre and meeting eligibility criteria were included. 10 The eligibility criteria were diagnosis with chronic HCV aged <18 years and being in routine follow-up at the participating centres.
Pseudonymized individual-patient data were retrospectively collected according to a standard protocol using the secure, web-based REDCap electronic data capture tool. 11 Additional data collection on treatment response and adverse events for the sub-group of children still undergoing treatment in July 2015 was conducted prospectively until May 2017, to obtain treatment outcome data.
Ethics approval for the study was obtained from the National 
| Definitions
Chronic HCV was defined as detectable HCV RNA in two or more blood samples at least 6 months apart. For children not vertically infected, duration of diagnosed infection was calculated as time from date of diagnosis.
The mode of transmission was reported by participating clinics as vertical (mother is known to have HCV), suspected 205 treated with IFN-based regimens, 100 (49%) had SVR24. Most children (191, 93%) experienced adverse reactions, leading to treatment discontinuation in 6 (3%).
In conclusion, a third of children acquired HCV via nonvertical routes and a substantial proportion of those with liver biopsy had advanced liver disease. were categorized as normal (<5.0 kPa), mild increase (5.0 to <7.0 kPa), moderate (7.0 to <9.0 kPa) and severe increase (≥9.0 kPa); ≥9 kPa was taken as predictor of severe fibrosis (≥F3).
15,16
Successful outcome was defined as sustained virological response 24 weeks after the end of treatment (SVR24).
Heights were converted to height-for-age z-scores (HAZ) using the WHO Growth Standard for measurements at age <5 years old, 17 and WHO 2007 growth reference at age 5-18 years. 
| Statistical analysis

| RE SULTS
A total of 301 children under follow-up were included 101 were from Moscow, 100 from St Petersburg and 100 from Krasnoyarsk (Supporting information Table S1 ). Half were male (156, 52%), most were of white ethnicity (281, 93%), and born in Russia (297, 99% 
| Laboratory investigations
had platelets <150 × 10 
| Liver ultrasound
All children had liver ultrasound results reported. At last, ultrasound 171 (57%) had normal liver, 113 (38%) had increased echogenicity, 96 (32%) heterogeneous structure (86 (29%) had both), 11 (4%) had steatosis and 15 (5%) had signs of portal hypertension.
| Liver biopsy
Ninety-two (31%) children had a liver biopsy (four children had two),
with median age at last biopsy of 9.4 [IQR 6.1, 13.0] years (Table 1 ).
The likelihood of having had a liver biopsy increased with age; at last follow-up six of 52 (12%) children aged <5 years had had a biopsy compared to 27 of 102 (26%) 6-to 10-year-olds, 31 of 92 (34%) 11-to 15-year-olds and 28 of 55 (51%) aged >15 years (P < 0.001). Fortytwo (21%) vertically infected children had a biopsy vs 50 (48%) of those with nonvertical infection but this difference was nonsignificant after adjusting for age (P = 0.898). There was significant variation by centre with 68 (67%) of children at the Moscow centre having had a biopsy compared to 11 (11%) in St Petersburg and 13 (13%) in Krasnoyarsk (P < 0.001).
At last biopsy, 38 (41%) had signs of bridging fibrosis; median age at diagnosis was 10.4 [7.1, 14.1] years, with range of 2.1-17.8 years.
Cirrhosis was identified at liver biopsy in one 15-year-old adolescent in whom infection acquired through contaminated blood products was diagnosed 7 months prior to biopsy. Rates of bridging fibrosis or cirrhosis at the last biopsy are summarized in Table 1 .
| Transient elastography
A total of 345 TE measurements were reported in 223 (74%) children. Results of the last TE are summarized in Table 2 . There was a significant association between older age at TE and increased liver stiffness (r = 0.22, P = 0.001) ( Figure 1 ). Moderate increase in liver stiffness (≥7 kPa) was not seen in children <7. 5.2 (SD 1.7) to 4.6 (SD 1.6) between the first and last TE (P < 0.001) (Supporting Information Figure S3 ).
In multivariable random effects analysis of all available TE results, there was no association between mode of infection (P = 0.577), sex (P = 0.625) and genotype (P = 0.269) but for every 1 year increase in age at TE mean stiffness increased by 0.09 kPa (95% CI 0.05, 0.13, P < 0.001). Mean liver stiffness was 1.1 kPa (0.7, 1.5, P < 0.001) lower at both St Petersburg and Krasnoyarsk centres than in Moscow.
| Comparison of biopsy and transient elastography results
Sixty-four children had both a biopsy and a scan. 
| Treatment
Overall, 205 (68%) children received treatment, most commonly pegylated interferon (PegIFN) alfa-2b and ribavirin (RBV); 37 (18%) received >1 treatment course. Median duration was 16 [14, 28] months.
Indications for the last treatment were evidence of fibrosis on liver (Table 3) . Six children required treatment with antidepressants and one required thyroxin replacement. Across all 205 treated children, 54 (26%) had dose reduction and/or discontinuation.
Thirty-nine (19%) children prematurely discontinued the last course of treatment: 33 (16%) for inadequate response and 6 (3%) for drug reactions.
HCV results 24 weeks post-treatment discontinuation were available for all treated patients, 100 (49%) of whom had SVR24 (Table 3) (37%) on other treatments (Table 3) . Of those treated with PegIFN alfa-2b/RBV, 65 (57%) achieved SVR24 overall (35 (55%) with GT1, and 30 (61%) with GT2/3) (Table 4) . SVR24 was more common in those vertically infected (P = 0.014), but the difference disappeared after adjusting for age at treatment start (P = 0.216). Nonvertically infected children also had a higher rate of treatment discontinuation (Supporting information Table S2 ). Treatment outcomes varied significantly by centre, with the lowest proportion of patients with SVR24 in Moscow (34%) and the highest in Krasnoyarsk (74%) (Supporting information Table S1 ). The Moscow cohort had more complex patients, more patients diagnosed at older ages and more with clinical symptoms or elevated transaminases at diagnosis. More patients in Moscow also had increased liver stiffness measured by TE and bridging fibrosis on liver biopsy suggesting more progressive disease (Tables 1 and 2 ; Supporting information Table S1 ). Higher treatment discontinuations in the Moscow cohort (31% vs 15% St Petersburg and 8% Krasnoyarsk) (Supporting information Table S1) also partially explain the centre differences in cure rates. 
| D ISCUSS I ON
Russia has one of the largest populations of children living with HCV in Europe; however there are scarce data on CHC in children in peerreviewed literature published outside Russia. This study contributes to addressing this knowledge gap by providing detailed characterization of a large number of children and adolescents with CHC, of whom 65% were vertically infected.
The most frequent reason for HCV testing was HCV infection
in a family member, usually the mother, which coincided with the predominance of vertical mode of transmission in the study and with national surveillance data. 6 Vertical transmission of HCV so far remains the only nonpreventable route of acquisition of hepatitis C infection in children. Notably, the observed proportion of vertical infection is lower here compared to that reported in western European children.
19
The finding that infection possibly acquired via transfusion of blood components or through invasive procedures comprised nearly a quarter of all cases here is important. In the national surveillance report, a similar proportion of children had unknown mode of transmission. 6 A recent outbreak of hospital-acquired HCV infection at a Russian children's hospital in the Amur region highlights the significance of the problem. Three-quarters of children had evaluation of liver stiffness by TE, used as indirect assessment of liver fibrosis. Greater liver stiffness was observed with older age and duration of infection, although only two (1%) children had liver stiffness indicative of advanced fibrosis (≥9 kPA) and six (3%) had a moderate increase (7 to <9 kPa); 7% of children over 10 years of age had a moderate or severe increase. The paired TE and liver biopsy results were available for children with initial stages of liver disease (F0-F2) ; no children with F3 or F4 had TE as all of them had liver biopsy before TE was introduced in the centres. This could be a possible explanation for the weak correlation between TE and liver biopsy results here. Drawbacks of using TE for evaluation of liver disease staging have high inter-patient variation, lack of correlation between TE and liver biopsy for nonadvanced liver fibrosis and absence of validated data for children with CHC.
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High inter-and intra-observer variability of liver biopsy evaluation 23 and different biopsy scoring systems add to these limitations. At Duration of treatment (mo) All 16 [14, 28] 21 [14, 28] 17 [14, 18] 16 [14, 28] 15 [11, 27] Genotype 1a/b 28 [16, 28] 28 [28, 28] 16 [14, 23] 17 [15, 28] 27 [8, 28] Genotype 2/3 14 [14, 15] 14 [14, 14] 15 [14, 17] 15 [14, 26] 15 [14, 16] Treatment prematurely discontinued 39 (19) 12 (11) 3 (23) 18 (31) (7) 1 (1) 2 (15) 10 (17) 1 (5) Hypersensitivity reaction 6 (3) 6 (5) 0 0 0
Nausea/vomiting 20 (10) 17 (15) 1 (8) 2 (3) 0 (37) 7 (37) IQR, interquartile range. a More than one adverse event or discontinuation reason may be reported in the same child. Multiple adverse events were reported in the six children who discontinued due to drug reactions including hypersensitivity (n = 2), weakness (n = 2), depression/anxiety (n = 4), anaemia (n = 2), alopecia (n = 3) and insomnia (n = 1). present, it is not possible to confidently identify rapid CHC progressors with non-invasive tests, and liver biopsy remains a gold standard for liver disease staging, despite being an invasive, expensive and operator-dependant procedure requiring technical and pathology expertise and general anaesthetic in younger children. There is a pressing need of a large high-quality study validating TE against liver it is associated with substantial toxicity and has suboptimal efficacy.
Over two-thirds of children in this study were treated. Only 57% of children treated with PegIFN/RBV achieved SVR24, similar to the results of a meta-analysis demonstrating 58% of overall SVR across genotypes; rates of treatment discontinuation due to adverse events were also similar. 31 The proportion of children with SVR24 was lowest in Moscow, which might be explained by their more complex patients, and also their treatment of children from across Russia, with joint follow-up with local hepatitis C clinics potentially contributing to more frequent treatment discontinuations. This highlights the difficulties of treating children with prolonged IFN-based schemes, especially those living in remote settings.
Most treated children in our study experienced adverse events.
Of those treated with PegIFN/RBV, one in three developed anaemia or neutropenia, one in three had hair loss and one in six suffered from anxiety/depression; the latter may be underestimated given that young children do not understand or communicate these adverse events well. Consistent with previous studies, [32] [33] [34] we showed that growth was adversely affected during treatment, particularly among young adolescents.
Our results confirm that currently used regimens have suboptimal outcomes and very poor safety profiles. Today, when DAAs can achieve cure rates of more than 95%, it seems unethical to treat patients with IFN-based regimens with suboptimal response rates and nearly universal occurrence of adverse reactions as indicated by a 93% rate in this study. However, only IFN-based regimes are currently approved for paediatric treatment in Russia. For DAAs to be licensed in children, it is required that paediatric studies are conducted in Russia which presents an additional hurdle to making DAAs accessible to children. Clinicians, regulatory authorities and the community health sector should work together to expedite the process. Outside Russia, at present only two drugs (sofosbuvir and ledipasvir) are licensed for adolescents aged ≥12 years by the FDA and EMA; paediatric access to these drugs is delayed in most countries, with prohibitive costs. Middle-income countries are in a particularly difficult situation as they are excluded from voluntary licensing agreements and compulsory licensing is challenging to implement. 35, 36 We showed that patients completing treatment had a significant decrease of liver stiffness measured by TE, suggesting that treatment in childhood maybe beneficial.
In the absence of DAA-regimens for children, the only treatment 
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